{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:17:39Z","timestamp":1775312259952,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013778","name":"Appendix Cancer Pseudomyxoma Peritonei Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.soc.2024.11.002","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T21:25:36Z","timestamp":1734557136000},"page":"133-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overview"],"prefix":"10.1016","volume":"34","author":[{"given":"Mathangi","family":"Chandramouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?","volume":"257","author":"Go\u00e9r\u00e9","year":"2013","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1245\/s10434-020-08315-x","article-title":"The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases","volume":"27","author":"Group","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","article-title":"2022 peritoneal surface oncology group international consensus on HIPEC regimens for peritoneal malignancies: colorectal cancer","volume":"31","author":"H\u00fcbner","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.11.002_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/XCS.0000000000000937","article-title":"International expert consensus on defining textbook oncologic outcomes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis","volume":"238","author":"Zohar","year":"2024","journal-title":"J\u00a0Am Coll Surg"},{"issue":"9","key":"10.1016\/j.soc.2024.11.002_bib6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s43018-021-00240-6","article-title":"Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities","volume":"2","author":"Tanaka","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib7","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1038\/s41467-022-32198-z","article-title":"Molecular characterization of colorectal cancer related peritoneal metastatic disease","volume":"13","author":"Lenos","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.soc.2024.11.002_bib8","doi-asserted-by":"crossref","first-page":"e15914","DOI":"10.15252\/emmm.202215914","article-title":"The molecular biology of peritoneal metastatic disease","volume":"15","author":"Bootsma","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.soc.2024.11.002_bib9","series-title":"Digestive system tumours","year":"2019"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib10","doi-asserted-by":"crossref","first-page":"864","DOI":"10.5858\/134.6.864","article-title":"Appendiceal mucinous neoplasms: controversial issues","volume":"134","author":"Misdraji","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.soc.2024.11.002_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/1097-0142(19950201)75:3<757::AID-CNCR2820750303>3.0.CO;2-F","article-title":"Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors","volume":"75","author":"Carr","year":"1995","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00000478-200308000-00006","article-title":"Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases","volume":"27","author":"Misdraji","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.pap.0000194625.05137.51","article-title":"Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification","volume":"12","author":"Pai","year":"2005","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.soc.2024.11.002_bib14","article-title":"Genomic landscape of appendiceal neoplasms","volume":"2","author":"Ang","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.22.01392","article-title":"Molecular classification of appendiceal adenocarcinoma","volume":"41","author":"Foote","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41379-019-0256-2","article-title":"Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants","volume":"32","author":"LaFramboise","year":"2019","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1016\/j.soc.2024.11.002_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells12151962","article-title":"The promise of epigenetics research in the treatment of appendiceal neoplasms","volume":"12","author":"Ladel","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1159\/000536219","article-title":"Genome-wide analysis of DNA methylation in pseudomyxoma peritonei originated from appendiceal neoplasms","volume":"102","author":"Takane","year":"2024","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A\u00a0consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified delphi process","volume":"40","author":"Carr","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.soc.2024.11.002_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2214\/AJR.16.16646","article-title":"What the radiologist should know about treatment of peritoneal malignancy","volume":"208","author":"Aherne","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib21","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00330-019-06524-x","article-title":"Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis","volume":"30","author":"van 't Sant","year":"2020","journal-title":"Eur Radiol"},{"issue":"18","key":"10.1016\/j.soc.2024.11.002_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184348","article-title":"Detection of experimental colorectal peritoneal metastases by a novel PDGFR\u03b2-targeting nanobody","volume":"14","author":"Strating","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3348\/kjr.2023.0840","article-title":"Imaging evaluation of peritoneal metastasis: current and promising techniques","volume":"25","author":"Fu","year":"2024","journal-title":"Korean J Radiol"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib24","doi-asserted-by":"crossref","first-page":"e240260","DOI":"10.1001\/jamanetworkopen.2024.0260","article-title":"Serum tumor markers and outcomes in patients with appendiceal adenocarcinoma","volume":"7","author":"Yousef","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1245\/s10434-012-2627-5","article-title":"Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin","volume":"20","author":"Wagner","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.11.002_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ans.18078","article-title":"The utility of ctDNA in colorectal cancer with peritoneal metastases","volume":"93","author":"Xue","year":"2023","journal-title":"ANZ J Surg"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/SLA.0000000000005856","article-title":"Role of tumor-informed personalized circulating tumor DNA assay in informing recurrence in patients with peritoneal metastases from colorectal and high-grade appendix cancer undergoing curative-intent surgery","volume":"278","author":"Dhiman","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2024.11.002_bib28","doi-asserted-by":"crossref","first-page":"e2200572","DOI":"10.1200\/PO.22.00572","article-title":"Highly sensitive circulating tumor DNA assay aids clinical management of radiographically occult isolated peritoneal metastases in patients with GI cancer","volume":"7","author":"Singh","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.soc.2024.11.002_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920981351","article-title":"Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"12","author":"L\u00f3pez-Rojo","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12029-023-00959-8","article-title":"Role of circulating tumor DNA among patients with colorectal peritoneal metastases","volume":"55","author":"Baumgartner","year":"2024","journal-title":"J\u00a0Gastrointest Cancer"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib31","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","article-title":"Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival","volume":"25","author":"Baumgartner","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"16_suppl","key":"10.1016\/j.soc.2024.11.002_bib32","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2023.41.16_suppl.2606","article-title":"Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer","volume":"41","author":"Yuan","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib33","first-page":"1","article-title":"Society of Surgical Oncology SSO 2024 Annual Meeting","volume":"31","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13148-023-01479-9","article-title":"Peritoneal cell-free DNA as a sensitive biomarker for detection of peritoneal metastasis in colorectal cancer: a prospective diagnostic study: a prospective diagnostic study","volume":"15","author":"Yuan","year":"2023","journal-title":"Clin Epigenetics"},{"issue":"7","key":"10.1016\/j.soc.2024.11.002_bib35","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1245\/s10434-021-09627-2","article-title":"Impact of socioeconomic status on presentation and outcomes in colorectal peritoneal metastases following cytoreduction and chemoperfusion: persistent inequalities in outcomes at a high-volume center","volume":"28","author":"Rieser","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2024.11.002_bib36","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1245\/s10434-023-14074-2","article-title":"Neighborhood-level socioeconomic disadvantage predicts outcomes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy","volume":"30","author":"Winicki","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.11.002_bib37","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.soi.2024.100080","article-title":"Navigation needs in peritoneal surface malignancy as perceived by patients, caregivers and providers","volume":"1","author":"Lewis","year":"2024","journal-title":"Surgical Oncology Insight"},{"issue":"13","key":"10.1016\/j.soc.2024.11.002_bib38","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/bjs.9674","article-title":"Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"101","author":"Kusamura","year":"2014","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000522310","article-title":"Incomplete cytoreduction of colorectal cancer peritoneal metastases: survival outcomes by a cytoreduction score","volume":"38","author":"Sugarbaker","year":"2022","journal-title":"Visc Med"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib40","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1245\/s10434-007-9348-1","article-title":"Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43\u00b0C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients","volume":"14","author":"Elias","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib41","doi-asserted-by":"crossref","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","article-title":"Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures","volume":"2","author":"Foster","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.amjsurg.2008.06.037","article-title":"Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy","volume":"196","author":"Reuter","year":"2008","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1245\/s10434-022-12691-x","article-title":"Functional outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective cohort study","volume":"30","author":"Makker","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1245\/ASO.2004.05.009","article-title":"Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma","volume":"11","author":"Shen","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.soc.2024.11.002_bib45","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.3390\/cancers14235824","article-title":"Complications and mortality rate of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Italian peritoneal surface malignancies oncoteam results analysis","volume":"14","author":"Carboni","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib46","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1245\/s10434-019-07415-7","article-title":"Preoperative nutrition status and postoperative outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"26","author":"Reece","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib47","first-page":"2","article-title":"Nutrition care for the patient undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"46","author":"Figueiroa","year":"2024","journal-title":"Support Line (Chic)"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejso.2020.01.032","article-title":"Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy","volume":"47","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.11.002_bib49","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejso.2023.02.015","article-title":"Perioperative nutritional assessment and interventions in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a systematic review","volume":"49","author":"Gearing","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2024.11.002_bib50","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/nu13072147","article-title":"Effect of preoperative immunonutrition on postoperative major morbidity after cytoreductive surgery and HIPEC in patients with peritoneal metastasis","volume":"13","author":"Fern\u00e1ndez-Candela","year":"2021","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.soc.2024.11.002_bib51","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamasurg.2023.0198","article-title":"Effect of multimodal prehabilitation on reducing postoperative complications and enhancing functional capacity following colorectal cancer surgery: the PREHAB randomized clinical trial","volume":"158","author":"Molenaar","year":"2023","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09492-6","article-title":"PRehabIlitatiOn with pReoperatIve exercise and educaTion for patients undergoing major abdominal cancer surgerY: protocol for a multicentre randomised controlled TRIAL (PRIORITY TRIAL)","volume":"22","author":"Steffens","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.soc.2024.11.002_bib53","doi-asserted-by":"crossref","first-page":"200767","DOI":"10.1016\/j.omton.2024.200767","article-title":"Emerging therapeutic approaches for peritoneal metastases from gastrointestinal cancers","volume":"32","author":"Sikora","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.11.002_bib54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamasurg.2021.1642","article-title":"Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial","volume":"156","author":"Rovers","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.soc.2024.11.002_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221112478","article-title":"The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions","volume":"14","author":"Strach","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.11.002_bib56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/2767-9764.CRC-24-0019","article-title":"Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma","volume":"4","author":"Hornstein","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.soc.2024.11.002_bib57","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/cam4.2847","article-title":"Rational application of targeted therapeutics in mucinous colon\/appendix cancers with positive predictive factors","volume":"9","author":"Dilly","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.soc.2024.11.002_bib58","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.trsl.2015.03.004","article-title":"Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth","volume":"166","author":"Dilly","year":"2015","journal-title":"Transl Res"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib59","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000477562","article-title":"Clinical benefit from trametinib in a patient with appendiceal adenocarcinoma with a","volume":"10","author":"Ang","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.11.002_bib60","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1245\/s10434-023-14553-6","article-title":"Characterizing the immune environment in peritoneal carcinomatosis: insights for novel immunotherapy strategies","volume":"31","author":"Wagner","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4_suppl","key":"10.1016\/j.soc.2024.11.002_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2023.41.4_suppl.217","article-title":"Characteristics of immune-infiltrating cells in the tumor microenvironment of appendiceal cancer with peritoneal disease","volume":"41","author":"Strach","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib62","doi-asserted-by":"crossref","first-page":"100042","DOI":"10.1016\/j.soi.2024.100042","article-title":"Intra-tumoral immunomodulatory therapy for advanced abdominal cancers using lipopolysaccharide: the Regional Immuno-Oncology Trial-1 (RIOT-1) protocol (NCT05751837)","volume":"1","author":"Lewis","year":"2024","journal-title":"Surgical Oncology Insight"},{"issue":"2","key":"10.1016\/j.soc.2024.11.002_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.soi.2024.100045","article-title":"Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: the Regional Immuno-Oncology Trial (RIOT)\u22122 study protocol","volume":"1","author":"Park","year":"2024","journal-title":"Surgical Oncology Insight"},{"issue":"4","key":"10.1016\/j.soc.2024.11.002_bib64","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1245\/s10434-018-07120-x","article-title":"Characterizing the patient experience of CS\/HIPEC through in-depth interviews with patients: identification of key concepts in the development of a patient-centered program","volume":"26","author":"Francescutti","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.11.002_bib65","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1245\/s10434-016-5203-6","article-title":"Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"23","author":"Chia","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.11.002_bib66","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1245\/s10434-016-5692-3","article-title":"Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS\/HIPEC) and perioperative practices: an international survey of high-volume surgeons","volume":"24","author":"Maciver","year":"2017","journal-title":"Ann Surg Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:46:26Z","timestamp":1750862786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320724000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1055320724000826"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2024.11.002","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2024.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}